Products for Research Use Only

Molnupiravir-d7

CAT: 0804-HY-135853S-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-135853S-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Molnupiravir-d7 is the deuterium labeled Molnupiravir. Molnupiravir (EIDD-2801) is an orally bioavailable prodrug of the ribonucleoside analog EIDD-1931. Molnupiravir has broad spectrum antiviral activity against influenza virus and multiple coronaviruses, such as SARS-CoV-2, MERS-CoV, SARS-CoV. Molnupiravir has the potential for the research of COVID-19, and seasonal and pandemic influenza[1][2].
Product Name Alternative
EIDD-2801-d7; MK-4482-d7
UNSPSC
12352005
Target
Influenza Virus; SARS-CoV
Type
Isotope-Labeled Compounds
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology
Purity
99.86
Solubility
10 mM in DMSO|DMSO : 50mg/mL (ultrasonic) |H2O : 12.5mg/mL (ultrasonic)
Smiles
O=C(N([C@@]1([H])[C@H](O)[C@H](O)[C@@]([H])(COC(C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)O1)C=C2)NC2=NO
Molecular Formula
C13H12D7N3O7
Molecular Weight
336.35
References & Citations
[1]Sheahan TP, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 Apr 6. pii: eabb5883. |[2]Toots M, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019 Oct 23;11 (515) . pii: eaax5866.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported